Validation of an Intermittent Shuttle Walking Protocol in Patients With COPD
Launched by NORTHUMBRIA UNIVERSITY · Mar 26, 2020
Trial Information
Current as of April 26, 2025
Unknown status
Keywords
ClinConnect Summary
Although previous research in the area of pulmonary rehabilitation in COPD has documented that high intensity exercise induces greater benefits than moderate intensity exercise, patients with advanced COPD patients cannot sustain sufficiently high intensities for long periods of time due to exertional breathlessness. While patients are limited by breathlessness during continuous modes of exercise, intermittent exercise is considered to be a good alternative strategy for patients with advanced COPD as it is associated with reduced exertional symptoms. Intermittent exercise consists of repeat...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female aged 40 years or older.
- • 2. Current or previous smoking history: 10 or more pack years.
- Exclusion Criteria:
- • 1. Orthopaedic, neurological or other concomitant diseases that significantly impair normal biomechanical movement patterns, as judged by the investigator.
- • 2. Moderate or severe COPD exacerbation within 6 weeks.
- • 3. Unstable cardiac arrhythmia.
- • 4. Unstable ischaemic heart disease, including myocardial infarction within 6 weeks.
- • 5. Moderate or severe aortic stenosis or hypertrophic obstructive cardiomyopathy.
About Northumbria University
Northumbria University is a leading research-intensive institution based in the UK, dedicated to advancing knowledge and innovation in various fields, including health sciences. As a clinical trial sponsor, the university leverages its academic expertise and state-of-the-art facilities to conduct high-quality research aimed at improving patient outcomes and informing clinical practices. With a commitment to ethical standards and regulatory compliance, Northumbria University collaborates with healthcare professionals and industry partners to explore novel therapeutic interventions and contribute to the body of evidence that shapes modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials